MYCENAX
BEST PARTNER

Mycenax Biotech Inc.

Board of Directors' Expertise and Diversity

1. Board of Directors Diversity Policy

On March 10, 2022, Mycenax's Board of Directors revised the "Corporate Governance Best Practice Principles." Chapter three, "Enhancing Board Functions," states that diversity should be considered when forming Board members, and the Directors concurrently serving as company officers shall not exceed one-third of the Board. An appropriate policy on diversity based on Mycenax's business operations and development must be formulated and include, without being limited to, the following two guidelines:

• **Basic requirements**

Gender, age, nationality, and culture, among which the proportion of female directors should preferably reach one-third of the Board seats.

• **Professional knowledge and skills**

Board members should generally possess the knowledge, skills, and qualities necessary to perform their duties, including a professional background (e.g., law, accounting, industry, finance, marketing or technology), skills and industry experience.

In addition to the aforementioned diversity policy, the specific management objectives of the Company's Board diversity are as follows:

- At least one-third of the directors shall be female.
- At least one-third of the directors shall have a professional background in the biotechnology industry, with at least one director possessing expertise in finance and accounting, and at least one director possessing expertise in law.

2. Implementation

The current 11th Board of Directors currently consists of 8 members, including 3 female directors, reaching one-third of the total board seats. Our board members possess diverse and complementary expertise across various industrial fields. Specifically, 3 members have professional backgrounds in biotechnology, 5 in finance and accounting, and 1 in law. In summary, the Company's board members possess a broad range of experience and capabilities, demonstrating that the Board of Directors has successfully achieved its specific management objectives for diversity.

Diversity Items			Gender	Nationality	Age	Professional Ability			Industry Experiences	Note
						Biotechnology	Finance /Accounting	Legal Practice		
1	Chairman	Pei-Jiun Chen	Female	R.O.C	51-60	V			V	
2	Director	Chun-Hong Chen	Male	R.O.C	61-70		V		V	
3	Director	Yi-Hsin Lee	Female	R.O.C	41-50		V		V	
4	Director	Jung-Chin Lin	Male	R.O.C	71-80	V	V		V	
5	Independent Director	Kuo-Pin Kao	Male	R.O.C	61-70		V		V	
6	Independent Director	Yu-Sheng Tsai	Male	R.O.C	51-60			V	V	
7	Independent Director	Kuo-Lung Yen	Male	R.O.C	61-70		V		V	
8	Independent Director	Maggie Lu	Female	R.O.C	51-60	V			V	

(The information above is based on current 8 seat of directors)

①There are 4 independent directors (an increase from the previous term), accounting for 50%.

②The company has 3 female directors, accounting for 37.5%; and 5 male directors, accounting for 62.5%.

③ The age distribution of the company's directors is as follows: 1 director is over 70 years old, accounting for 12.5%; 3 directors are between 61 and 70 years old, accounting for 37.5%; 3 director is between 51 and 60 years old, accounting for 37.5%; and 1 directors are under 50 years old, accounting for 12.5%.

④ There are 3 directors with a professional background in the biotechnology industry, accounting for 37.5%; all 8 directors have industry experience, accounting for 100%.

⑤ There are no directors related by marriage or within the second degree of kinship, in compliance with the provisions of Article 26-3, Paragraphs 3 and 4 of the Securities and Exchange Act.